Staff Writer

The indication for the DigniCap Cooling System has been expanded by the FDA to include alopecia reduction across all solid tumors.

Patients treated with cisplatin-based chemotherapy had a higher risk of venous thromboembolism.

An ongoing trial is evaluating the addition of PARP inhibitor velaparib to a chemotherapy combination, for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.

An ongoing trial is evaluating the combination therapy of interleukin-10 agonist AM0010 and FOLFOX chemotherapy, for patients with metastatic pancreatic cancer.

For patients with BRCA+ ovarian cancer, olaparib in the maintenance setting has shown impressive progression free survival benefits.

According to a recent survey, the main causes for a lack of HPV vaccine uptake are a lack of knowledge and a failure by healthcare providers to recommend it.

The FDA has granted accelerated approval of ibrutinib for treatment of marginal zone lymphona (MZL).

A recent survey indicates that many patients with MPNs experience a high symptom burden that affects their emotional wellbeing, quality of life, and functionality.

In a recent phase III study, the PARP-inhibitor olaparib was shown to improve progression-free survival for patients with BRCA-positive ovarian cancer.

An update on CDK4 and CDK6 inhibitors in treatment for patients with metastatic breast cancer.

For patients with HR-positive breast cancer, fulvestrant proved to be better for PFS than anastrozole.

Olaratumab (Lartruvo) has been granted an accelerated approval from the FDA for the treatment of patients with advanced soft tissue sarcoma.

A recent study shows CDK inhibitor ribociclib reduces progression of HR-positive metastatic breast cancer.

Pelvic IMRT causes less GI, GU toxicities than standard pelvic radiation therapy for patients with gynecologic cancers.

Harold P. Freeman, MD, who developed the patient navigation concept now used widely in cancer care, was honored in the Community Outreach/Education category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Findings from a randomized trial reported at the 2016 Annual Meeting of the Society of Gynecologic Oncology showed that APF530, an extended-release formulation of the antiemetic granisetron, achieved a complete response more often than did ondansetron in patients receiving highly emetogenic cisplatin-based chemotherapy.

Less than 50% of patients with ovarian cancer who could benefit from intraperitoneal chemotherapy actually receive it, despite research suggesting that this technique could improve survival for these patients.

The FDA has granted an accelerated approval to ibrutinib (Imbruvica) as a treatment for patients with chronic lymphocytic leukemia

Eltrombopag (Promacta), a small molecule thrombopoietin receptor (TPOR) agonist, has received a Breakthrough Therapy designation from the FDA for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.

The FDA has approved the first-ever targeted therapy combination for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation